POM-V
Prescription Required
Companion Animal
Depo-Medrone V 40 mg/ml Suspension for Injection for Dogs, Cats, and Horses
Active ingredient: Methylprednisolone Acetate
Form
Injection
Species
Cats
Dogs
Horses
Manufacturer
Zoetis Belgium S.A.
VMD MA No.
60021/3008
What it's used for
Injectable corticosteroid in dogs, cats and horses. For the treatment of, or as part of a therapeutic regime for, inflammatory and allergic conditions in d...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Methylprednisolone Acetate
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Depo-Medrone V 40 mg/ml Suspension for Injection for Dogs, Cats, and Horses — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.
Injectable corticosteroid in dogs, cats and horses.
For the treatment of, or as part of a therapeutic regime for, inflammatory and
allergic conditions in dogs and cats such as allergic or non-specific
inflammatory dermal conditions, musculo-skeletal conditions, ocular/otic
inflammatory conditions and other inflammatory/allergic conditions that are
likely to respond to corticosteroid therapy e.g. autoimmune disorders. For the
treatment of, or as part of a therapeutic regime for, musculo-skeletal conditions
in horses.
For the treatment of, or as part of a therapeutic regime for, inflammatory and
allergic conditions in dogs and cats such as allergic or non-specific
inflammatory dermal conditions, musculo-skeletal conditions, ocular/otic
inflammatory conditions and other inflammatory/allergic conditions that are
likely to respond to corticosteroid therapy e.g. autoimmune disorders. For the
treatment of, or as part of a therapeutic regime for, musculo-skeletal conditions
in horses.
The dosage needed may vary according to individual clinical circumstances
such as the severity of the condition to be treated, size of animal, and clinical
response.
The following dosage recommendations are therefore initial guidelines and may
need slight alteration in the light of individual response. An insulin type syringe
should be used to measure and administer volumes of less than 1ml.
Local: Aseptic precautions are important.
Horses:
Smaller spaces will require a correspondingly lesser dose. The intratendinous
dose ranges from 80-400 mg (2-10 ml) depending on the size of the tendon.
Revised: November 2025
AN: 02177/2025
Dogs:
Smaller spaces will require a correspondingly lesser dosage.
Procedure for intrasynovial injection:
should be reviewed in order to ensure that the product is properly placed and
that large blood vessels and nerves are avoided. The injection site is located
where the synovial cavity is most superficial. The area is prepared for aseptic
injection by shaving and disinfection. If there is an excess of synovia and more
than 1 ml of the product is to be injected, it is advisable to aspirate a volume of
fluid comparable to that which is to be injected. With the needle in place, the
aspirating syringe is removed and replaced by a second syringe containing the
proper amount of the product to be injected. In some animals, a transient pain or
synovial flare may be elicited immediately upon injection and may last for up to
two to three days. After injection, the structure may be moved gently a few times
to aid mixing of the synovial fluid and the product. The site may be covered with
a small sterile dressing.
Following injection, relief from clinical signs may be experienced within 12-24
hours and be sustained for a variable period but averages three to four weeks,
with a range of one to more than five weeks. The continued or prolonged use of
the product is discouraged.
Intramuscular:
Horses:
Dogs and cats:
Injections may be repeated in accordance with the severity of the condition and
clinical response. Relief from clinical signs is usually sustained for up to three
weeks but may range from one to more than four weeks.
For maintenance therapy in chronic conditions, initial doses should be gradually
reduced until the smallest effective dose is established.
such as the severity of the condition to be treated, size of animal, and clinical
response.
The following dosage recommendations are therefore initial guidelines and may
need slight alteration in the light of individual response. An insulin type syringe
should be used to measure and administer volumes of less than 1ml.
Local: Aseptic precautions are important.
Horses:
Smaller spaces will require a correspondingly lesser dose. The intratendinous
dose ranges from 80-400 mg (2-10 ml) depending on the size of the tendon.
Revised: November 2025
AN: 02177/2025
Dogs:
Smaller spaces will require a correspondingly lesser dosage.
Procedure for intrasynovial injection:
should be reviewed in order to ensure that the product is properly placed and
that large blood vessels and nerves are avoided. The injection site is located
where the synovial cavity is most superficial. The area is prepared for aseptic
injection by shaving and disinfection. If there is an excess of synovia and more
than 1 ml of the product is to be injected, it is advisable to aspirate a volume of
fluid comparable to that which is to be injected. With the needle in place, the
aspirating syringe is removed and replaced by a second syringe containing the
proper amount of the product to be injected. In some animals, a transient pain or
synovial flare may be elicited immediately upon injection and may last for up to
two to three days. After injection, the structure may be moved gently a few times
to aid mixing of the synovial fluid and the product. The site may be covered with
a small sterile dressing.
Following injection, relief from clinical signs may be experienced within 12-24
hours and be sustained for a variable period but averages three to four weeks,
with a range of one to more than five weeks. The continued or prolonged use of
the product is discouraged.
Intramuscular:
Horses:
Dogs and cats:
Injections may be repeated in accordance with the severity of the condition and
clinical response. Relief from clinical signs is usually sustained for up to three
weeks but may range from one to more than four weeks.
For maintenance therapy in chronic conditions, initial doses should be gradually
reduced until the smallest effective dose is established.
Not to be given intravenously. The technique of aspiration should be employed,
as appropriate, to avoid intravascular administration. Intrasynovial,
intratendinous or other injections of corticosteroids for local effect are contra-
indicated in the presence of acute infectious conditions.
Do not mix with any other product for injection at the same site.
Systemic corticosteroid therapy is generally contra-indicated in patients with
arrested tuberculosis, peptic ulcer, renal disease, diabetes mellitus and
Cushing's syndrome.
Revised: November 2025
AN: 02177/2025
The product is contra-indicated for the treatment of laminitis in horses.
as appropriate, to avoid intravascular administration. Intrasynovial,
intratendinous or other injections of corticosteroids for local effect are contra-
indicated in the presence of acute infectious conditions.
Do not mix with any other product for injection at the same site.
Systemic corticosteroid therapy is generally contra-indicated in patients with
arrested tuberculosis, peptic ulcer, renal disease, diabetes mellitus and
Cushing's syndrome.
Revised: November 2025
AN: 02177/2025
The product is contra-indicated for the treatment of laminitis in horses.
Anti-inflammatory corticosteroids, such as methylprednisolone, are known to
exert a wide range of side-effects. Whilst single high doses are generally well
tolerated, they may induce severe side-effects in long term use and when
esters possessing a long duration of action are administered. Dosage in
medium to long term use should therefore generally be kept to the minimum
necessary to control clinical signs. The continued or prolonged use of this
product is not generally recommended.
Steroids themselves, during treatment, may cause Cushingoid symptoms
involving significant alteration of fat, carbohydrate, protein and mineral
metabolism, e.g. redistribution of body fat, muscle weakness and wastage and
osteoporosis may result. During therapy, effective doses suppress the
Hypothalamo-Pituitary-Adrenal axis. Following cessation of treatment, signs of
adrenal insufficiency extending to adrenocortical atrophy can arise and this
may render the animal unable to deal adequately with stressful situations.
Consideration should therefore be given to means of minimising problems of
adrenal insufficiency following the withdrawal of treatment, e.g. a gradual
reduction of dosage (for further discussion see standard texts).
Revised: November 2025
AN: 02177/2025
Systemically administered corticosteroids may cause polyuria, polydipsia and
polyphagia, particularly during the early stages of therapy. Some
corticosteroids may cause sodium and water retention and hypokalaemia in
long term use. Locally applied steroids may cause thinning of the skin and
systemic corticosteroids have caused deposition of calcium in the skin
(calcinosis cutis).
Corticosteroids may delay wound healing and the immunosuppressant actions
may weaken resistance to or exacerbate existing infections. In the presence of
bacterial infection, anti-bacterial drug cover is usually required when steroids
are used. In the presence of viral infections, steroids may worsen or hasten the
progress of the disease.
Gastrointestinal ulceration has been reported in animals treated with
corticosteroids and gastrointestinal ulceration may be exacerbated by steroids
in patients given non-steroidal anti-inflammatory drugs and in corticosteroid
treated animals with spinal cord trauma. Steroids may cause enlargement of
the liver (hepatomegaly) with increased serum hepatic enzymes.
exert a wide range of side-effects. Whilst single high doses are generally well
tolerated, they may induce severe side-effects in long term use and when
esters possessing a long duration of action are administered. Dosage in
medium to long term use should therefore generally be kept to the minimum
necessary to control clinical signs. The continued or prolonged use of this
product is not generally recommended.
Steroids themselves, during treatment, may cause Cushingoid symptoms
involving significant alteration of fat, carbohydrate, protein and mineral
metabolism, e.g. redistribution of body fat, muscle weakness and wastage and
osteoporosis may result. During therapy, effective doses suppress the
Hypothalamo-Pituitary-Adrenal axis. Following cessation of treatment, signs of
adrenal insufficiency extending to adrenocortical atrophy can arise and this
may render the animal unable to deal adequately with stressful situations.
Consideration should therefore be given to means of minimising problems of
adrenal insufficiency following the withdrawal of treatment, e.g. a gradual
reduction of dosage (for further discussion see standard texts).
Revised: November 2025
AN: 02177/2025
Systemically administered corticosteroids may cause polyuria, polydipsia and
polyphagia, particularly during the early stages of therapy. Some
corticosteroids may cause sodium and water retention and hypokalaemia in
long term use. Locally applied steroids may cause thinning of the skin and
systemic corticosteroids have caused deposition of calcium in the skin
(calcinosis cutis).
Corticosteroids may delay wound healing and the immunosuppressant actions
may weaken resistance to or exacerbate existing infections. In the presence of
bacterial infection, anti-bacterial drug cover is usually required when steroids
are used. In the presence of viral infections, steroids may worsen or hasten the
progress of the disease.
Gastrointestinal ulceration has been reported in animals treated with
corticosteroids and gastrointestinal ulceration may be exacerbated by steroids
in patients given non-steroidal anti-inflammatory drugs and in corticosteroid
treated animals with spinal cord trauma. Steroids may cause enlargement of
the liver (hepatomegaly) with increased serum hepatic enzymes.
It is important that treatment of working or racing animals is followed by a
period of rest to allow resolution of the clinical condition.
The product is contra-indicated for the treatment of laminitis in horses.
Additionally it should be noted that use of the product in horses for other
conditions could induce laminitis and careful observations during the treatment
period should be made.
Due to the potential for local cosmetic effects, the sub-cutaneous use of this
product in show animals is not recommended.
i) Special precautions for use in animals
Aspetic injection techniques should be practised. An insulin type syringe
should be used to measure and administer volumes of less than 1ml. It
is recommended that Depo-Medrone V is not mixed with any other
product for injection at the same site. Exacerbation of pain, further loss
of joint motion, with fever and malaise following intrasynovial injection
may indicate that the condition has become septic and appropriate
antibacterial therapy should be instituted immediately. Animals receiving
corticosteroids should be monitored for signs of infection and, where
necessary, appropriate antimicrobial therapy instigated.
As with any corticosteroid, treatment of working or racing animals should
be followed by a period of rest to allow resolution of the clinical
condition.
It is recommended that, where joint therapy is indicated, a radiologic
examination is undertaken prior to treatment to evaluate the presence of
fractures. If fractures are present, corticosteroid therapy should only be
used with utmost caution if permanent damage is to be avoided.
Anti-inflammatory corticosteroids, such as methylprednisolone, are
known to exert a wide range of side-effects. Whilst single high doses are
generally well tolerated, they may induce severe side-effects in long
term use and when esters possessing a long duration of action are
administered. Dosage in medium to long term use should therefore
generally be kept to the minimum necessary to control clinical signs.
The continued or prolonged use of this product is not generally
recommended.
Steroids themselves, during treatment, may cause Cushingoid
symptoms involving significant alteration of fat, carbohydrate, protein
and mineral metabolism, e.g. redistribution of body fat, muscle
Revised: November 2025
AN: 02177/2025
weakness and wastage and osteoporosis may result. During therapy
effective doses suppress the Hypothalamo-Pituitary-Adrenal axis.
Following cessation of treatment, signs of adrenal insufficiency
extending to adrenocorticol atrophy can arise and this may render the
animal unable to deal adequately with stressful situations.
Consideration should therefore be given to means of minimising
problems of adrenal insufficiency following the withdrawal of treatment,
e.g. a gradual reduction of dosage (for further discussion see standard
texts).
Corticosteroids may delay wound healing and the immunosuppressant
actions may weaken resistance to or exacerbate existing infections. In
the presence of bacterial infection, anti-bacterial drug cover is usually
required when steroids are used. In the presence of viral infections,
steroids may worsen or hasten the progress of the disease.
During a course of treatment the clinical condition of the animal should
be reviewed regularly by close veterinary supervision.
ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Wear protective gloves when using this product.
Care must be taken to avoid accidental self-injection.
Accidental spillage onto the skin, should be washed off immediately with
soap and water.
period of rest to allow resolution of the clinical condition.
The product is contra-indicated for the treatment of laminitis in horses.
Additionally it should be noted that use of the product in horses for other
conditions could induce laminitis and careful observations during the treatment
period should be made.
Due to the potential for local cosmetic effects, the sub-cutaneous use of this
product in show animals is not recommended.
i) Special precautions for use in animals
Aspetic injection techniques should be practised. An insulin type syringe
should be used to measure and administer volumes of less than 1ml. It
is recommended that Depo-Medrone V is not mixed with any other
product for injection at the same site. Exacerbation of pain, further loss
of joint motion, with fever and malaise following intrasynovial injection
may indicate that the condition has become septic and appropriate
antibacterial therapy should be instituted immediately. Animals receiving
corticosteroids should be monitored for signs of infection and, where
necessary, appropriate antimicrobial therapy instigated.
As with any corticosteroid, treatment of working or racing animals should
be followed by a period of rest to allow resolution of the clinical
condition.
It is recommended that, where joint therapy is indicated, a radiologic
examination is undertaken prior to treatment to evaluate the presence of
fractures. If fractures are present, corticosteroid therapy should only be
used with utmost caution if permanent damage is to be avoided.
Anti-inflammatory corticosteroids, such as methylprednisolone, are
known to exert a wide range of side-effects. Whilst single high doses are
generally well tolerated, they may induce severe side-effects in long
term use and when esters possessing a long duration of action are
administered. Dosage in medium to long term use should therefore
generally be kept to the minimum necessary to control clinical signs.
The continued or prolonged use of this product is not generally
recommended.
Steroids themselves, during treatment, may cause Cushingoid
symptoms involving significant alteration of fat, carbohydrate, protein
and mineral metabolism, e.g. redistribution of body fat, muscle
Revised: November 2025
AN: 02177/2025
weakness and wastage and osteoporosis may result. During therapy
effective doses suppress the Hypothalamo-Pituitary-Adrenal axis.
Following cessation of treatment, signs of adrenal insufficiency
extending to adrenocorticol atrophy can arise and this may render the
animal unable to deal adequately with stressful situations.
Consideration should therefore be given to means of minimising
problems of adrenal insufficiency following the withdrawal of treatment,
e.g. a gradual reduction of dosage (for further discussion see standard
texts).
Corticosteroids may delay wound healing and the immunosuppressant
actions may weaken resistance to or exacerbate existing infections. In
the presence of bacterial infection, anti-bacterial drug cover is usually
required when steroids are used. In the presence of viral infections,
steroids may worsen or hasten the progress of the disease.
During a course of treatment the clinical condition of the animal should
be reviewed regularly by close veterinary supervision.
ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Wear protective gloves when using this product.
Care must be taken to avoid accidental self-injection.
Accidental spillage onto the skin, should be washed off immediately with
soap and water.
interaction
Concurrent administration of barbiturates, phenylbutazone, phenytoin or
rifampicin may enhance the metabolism and reduce the effects of
corticosteroids. Response to anticoagulants may also be reduced by
corticosteroids.
Concurrent administration of barbiturates, phenylbutazone, phenytoin or
rifampicin may enhance the metabolism and reduce the effects of
corticosteroids. Response to anticoagulants may also be reduced by
corticosteroids.
Do not store above 25°C. Do not freeze. Shake vial before use. Following
withdrawal of the first dose, use the product within 28 days. Discard unused
material.
withdrawal of the first dose, use the product within 28 days. Discard unused
material.
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse passport must have been declared as not intended for human
consumption under national horse passport legislation.
Revised: November 2025
AN: 02177/2025
5.
Treated horses may never be slaughtered for human consumption.
The horse passport must have been declared as not intended for human
consumption under national horse passport legislation.
Revised: November 2025
AN: 02177/2025
5.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Methylprednisolone Acetate
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in anti-inflammatory
Related Medications
Adequan 100 mg/ml Solution for Injection
POM-VPolysulphated Glycosaminoglycan
injection
Rx
Horses
Alcort 0.584 mg/ml Cutaneous Spray, Solution
POM-VHydrocortisone Aceponate
spray
Rx
Dogs
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.